Thinking about buying a “cheap” Maserati GranTurismo? This video breaks down everything you need before signing on the dotted line. We explore real‑world performance, handling, maintenance costs, ...
Hosted on MSN
Full press conference | Adam Silver on Seattle NBA expansion, tanking and what comes next
Adam Silver addressed Seattle and Las Vegas expansion, tanking, ownership questions and the NBA’s next steps Wednesday. Trump to Americans after requesting $1.5 trillion military budget: "We can’t ...
It’s a question posed by millions of smartphone users worldwide, with interest in on-screen personal training at an highest. Research firm Statista estimates ...
LONDON and CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a ...
"With pivotal laru-zova data expected in the second half of 2026, these funds will accelerate our commercial preparations for this potentially life-changing product, as well as advance and expand our ...
Round led by new investor Life Sciences at Goldman Sachs Alternatives with participation by new investor the Retinal Degeneration Fund, and supported by existing investors Funds will advance laru-zova ...
LANDSCAPE open-label trial to evaluate safety of laru-zova administered bilaterally LONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited ('Beacon ...
LONDON and CAMBRIDGE, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a ...
A gene therapy that targets a form of retinitis pigmentosa showed a signal to improve retinal function for up to 3 years after treatment, according to a small clinical trial. The phase 2 SKYLINE trial ...
Laru-zova was generally well-tolerated by SKYLINE participants through month 36 and DAWN participants at 9 months or beyond LONDON and CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Beacon ...
(MENAFN- GlobeNewsWire - Nasdaq) Data showed sustained improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally ...
LONDON/CAMBRIDGE - Beacon Therapeutics has announced positive interim results from two Phase 2 clinical trials evaluating its gene therapy candidate laru-zova in patients with X-linked retinitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results